NASDAQ:GNPX

Genprex Stock Forecast, Price & News

$3.66

-0.07 (-1.88 %)

(As of 06/11/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.56

▼

$3.78

50-Day Range

$3.11

▼

$4.87

52-Week Range

$2.78

▼

$7.72

Volume574,118 shs

Average Volume479,379 shs

Market Capitalization$173.34 million

P/E RatioN/A

Dividend YieldN/A

Beta-0.68

30 days | 90 days | 365 days | Advanced Chart

Receive GNPX News and Ratings via Email

Sign-up to receive the latest news and ratings for Genprex and its competitors with MarketBeat's FREE daily newsletter.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate - Nasdaq
June 11, 2021 | nasdaq.com

Companies Like Genprex (NASDAQ:GNPX) Are In A Position To Invest In Growth
June 11, 2021 | finance.yahoo.com

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series - Yahoo Finance
May 20, 2021 | finance.yahoo.com

InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present in Noble Capital Markets' Virtual Roadshow - StreetInsider.com
May 19, 2021 | streetinsider.com

Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
May 19, 2021 | finance.yahoo.com

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation Schedule for May Investor Conferences - StreetInsider.com
May 10, 2021 | streetinsider.com

Genprex to Participate in Upcoming May Investor Conferences - Business Wire
May 10, 2021 | businesswire.com

Genprex to Participate in Upcoming May Investor Conferences
May 10, 2021 | finance.yahoo.com

Genprex in-licenses additional gene therapy technologies to treat non-small cell lung cancer - Proactive Investors USA & Canada
May 9, 2021 | proactiveinvestors.com

Genprex Announces Centralized Institutional Review Board Approval for Acclaim-1 Clinical Trial in Non-Small Cell Lung Cancer - Yahoo Finance
May 7, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNPX
Previous Symbol
CUSIPN/A
CIK1595248
Webwww.genprex.com
Phone512-537-7997
Employees12
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.77 per share
Price / Book4.75

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares47,360,000
Market Cap$173.34 million
Next Earnings Date6/17/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.18 out of 5 stars

Medical Sector

978th out of 2,099 stocks

Pharmaceutical Preparations Industry

480th out of 831 stocks

3.5 Analyst's Opinion

Consensus Rating
Genprex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.00, Genprex has a forecasted upside of 91.3% from its current price of $3.66.
Amount of Analyst Coverage
Genprex has received no research coverage in the past 90 days.

2.4 Community Rank

Outperform Votes
Genprex has received 195 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Genprex has received 213 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Genprex has received 52.21% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Genprex and other stocks. Vote “Outperform” if you believe GNPX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNPX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Genprex does not currently pay a dividend.
Dividend Growth
Genprex does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Genprex insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 11.22% of the stock of Genprex is held by insiders.
Percentage Held by Institutions
Only 17.27% of the stock of Genprex is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Genprex is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Genprex is -6.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Genprex has a P/B Ratio of 4.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Genprex (NASDAQ:GNPX) Frequently Asked Questions

Is Genprex a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genprex in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Genprex stock.
View analyst ratings for Genprex or view top-rated stocks.

What stocks does MarketBeat like better than Genprex?

Wall Street analysts have given Genprex a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genprex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Genprex's next earnings date?

Genprex is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Genprex.

How were Genprex's earnings last quarter?

Genprex, Inc. (NASDAQ:GNPX) issued its quarterly earnings data on Sunday, May, 16th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02.
View Genprex's earnings history.

How has Genprex's stock been impacted by Coronavirus (COVID-19)?

Genprex's stock was trading at $2.42 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNPX stock has increased by 51.2% and is now trading at $3.66.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GNPX?

1 Wall Street analysts have issued 12 month target prices for Genprex's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Genprex's share price to reach $7.00 in the next year. This suggests a possible upside of 91.3% from the stock's current price.
View analysts' price targets for Genprex or view top-rated stocks among Wall Street analysts.

Who are Genprex's key executives?

Genprex's management team includes the following people:

Mr. John Rodney Varner, Co, Founder, Pres, CEO, Sec. & Chairman (Age 64, Pay $750.94k)
Mr. Ryan M. Confer M.S., Chief Financial Officer (Age 39, Pay $522.53k)
Ms. Catherine M. Vaczy, Exec. VP, Gen. Counsel & Chief Strategy Officer (Age 60, Pay $646.02k)
Mr. Michael T. Redman, Exec. VP & COO (Age 66)
Ms. Kalyn Dabbs, Sr. Mang. of Communications & Marketing
Mr. Thomas C. Gallagher Esq., Sr. VP of Intellectual Property & Licensing
Dr. William E. Gannon Jr., Member of Clinical Advisory Board & VP of Regulatory Affairs
Dr. Jack A. Roth F.A.C.S., FACS, M.D., Chairman of Scientific & Medical Advisory Board

Who are some of Genprex's key competitors?

Some companies that are related to Genprex include Clene (CLNN), KalVista Pharmaceuticals (KALV), Lexicon Pharmaceuticals (LXRX), Cara Therapeutics (CARA), Summit Therapeutics (SMMT), Gossamer Bio (GOSS), Emisphere Technologies (EMIS), AnaptysBio (ANAB), Marinus Pharmaceuticals (MRNS), Crinetics Pharmaceuticals (CRNX), Albireo Pharma (ALBO), ZIOPHARM Oncology (ZIOP), Clovis Oncology (CLVS), Evolus (EOLS) and Bolt Biotherapeutics (BOLT).
View all of GNPX's competitors.

What other stocks do shareholders of Genprex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genprex investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), OPKO Health (OPK), SCYNEXIS (SCYX), iBio (IBIO) and Advanced Micro Devices (AMD).

What is Genprex's stock symbol?

Genprex trades on the NASDAQ under the ticker symbol "GNPX."

Who are Genprex's major shareholders?

Genprex's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.22%), Geode Capital Management LLC (1.15%), Nuveen Asset Management LLC (0.85%), Northern Trust Corp (0.71%), Renaissance Technologies LLC (0.65%) and Millennium Management LLC (0.27%).
View institutional ownership trends for Genprex.

Which institutional investors are selling Genprex stock?

GNPX stock was sold by a variety of institutional investors in the last quarter, including Altium Capital Management LP, JPMorgan Chase & Co., AQR Capital Management LLC, Bank of New York Mellon Corp, Morgan Stanley, Northern Trust Corp, and Price T Rowe Associates Inc. MD.
View insider buying and selling activity for Genprex or view top insider-selling stocks.

Which institutional investors are buying Genprex stock?

GNPX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Millennium Management LLC, Geode Capital Management LLC, Royal Bank of Canada, Russell Investments Group Ltd., Iridian Asset Management LLC CT, and UBS Group AG.
View insider buying and selling activity for Genprex or or view top insider-buying stocks.

How do I buy shares of Genprex?

Shares of GNPX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genprex's stock price today?

One share of GNPX stock can currently be purchased for approximately $3.66.

How much money does Genprex make?

Genprex has a market capitalization of $173.34 million.

How many employees does Genprex have?

Genprex employs 12 workers across the globe.

What is Genprex's official website?

The official website for Genprex is www.genprex.com.

Where are Genprex's headquarters?

Genprex is headquartered at 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712.

How can I contact Genprex?

Genprex's mailing address is 1601 Trinity Street Suite 3.322, AUSTIN TX, 78712. The company can be reached via phone at 512-537-7997 or via email at [email protected]

This page was last updated on 6/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here